Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23749957 | 0.82 | TDP1 (0.40) | TDP1MAPTCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL29162274 | 0.80 | CYP3A4 (0.39) | TDP1CYP3A4 | |
| SCHEMBL7473964 | 0.77 | HRH4 (0.39) | KMT2A | |
| SCHEMBL7478802 | 0.76 | GRIN2D (0.35) | TDP1MAPTKMT2A | |
| SCHEMBL6683153 | 0.75 | TDP1 (0.34) | TDP1CYP3A4 | |
| SCHEMBL7472156 | 0.70 | GRIN2D (0.43) | TDP1MAPTKMT2ANPSR1L3MBTL1 | |
| SCHEMBL405486 | 0.69 | TDP1 (0.50) | TDP1 | |
| SCHEMBL29558616 | 0.69 | TDP1 (0.50) | TDP1 | |
| SCHEMBL405345 | 0.69 | ALDH1A1 (0.45) | TDP1MAPTCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL5722680 | 0.68 | TSHR (0.55) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0783495-B1 | QUINOXALINE DERIVATIVES USEFUL IN THERAPY | PFIZER LTD (GB) | 2002-02-27 | — | — | EP | disclosed |
| EP-0781279-B1 | QUINOXALINEDIONE NMDA RECEPTOR ANTAGONISTS | PFIZER LTD (GB) | 2001-06-13 | — | — | EP | disclosed |
| US-5852016-A | Quinoxaline derivatives useful in therapy | PFIZER INC. (US) | 1998-12-22 | — | — | US | disclosed |
| US-5783572-A | TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER INC. (US) | 1998-07-21 | — | — | US | disclosed |
| CN-1158610-A | Quinoxaline derivatives useful in therapy | PFIZER LTD (IE) | 1997-09-03 | — | — | CN | disclosed |
| EP-0783495-A1 | QUINOXALINE DERIVATIVES USEFUL IN THERAPY | Pfizer Limited (GB) | 1997-07-16 | — | — | EP | disclosed |
| EP-0781279-A1 | QUINOXALINEDIONE NMDA RECEPTOR ANTAGONISTS | Pfizer Limited (GB) | 1997-07-02 | — | — | EP | disclosed |
| WO-1996009295-A1 | QUINOXALINE DERIVATIVES USEFUL IN THERAPY | PFIZER LIMITED (GB) | 1996-03-28 | — | — | WO | disclosed |
| WO-1996008485-A1 | QUINOXALINEDIONE NMDA RECEPTOR ANTAGONISTS | PFIZER LIMITED (GB) | 1996-03-21 | — | — | WO | disclosed |